tirzepatide mash phase 3 Nearly 62% achieve resolution without worsening of fibrosis with Drug treatment of MASH from

Some observational studies of patients with type 2 diabetes suggest that GLP-1 receptor agonist use associates with reduced dementia risk compared with other glucose-lowering medications, but these findings require cautious interpretation due to potential confounding factors

We brought together a peptide studied in preclinical models for its role in gut barrier comfort, clinically researched pre- and probiotics to nourish the microbiome, and targeted tributyrin to deliver butyrate where its needed most

Both studies saw a respective reduction in A1C by 2.37% and 2.59% as well as body weight reductions of 13.9% and 11.6%

Final Thoughts Testosterone decline is not just an age issue it is heavily influenced by modern lifestyle, stress, pollution, processed foods, and environmental toxins